fenofibrate has been researched along with fibrinogen in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 7 (20.59) | 18.2507 |
| 2000's | 22 (64.71) | 29.6817 |
| 2010's | 4 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, H; Egbring, R; Höffken, H; Joseph, K; Leschke, M; Schmidtsdorff, A; Strauer, BE | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Ceska, R; Haas, T; Kvasilová, M; Kvasnicka, J; Procházková, R; Sobra, J | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Belichard, P; Bontemps, L; de Lorgeril, M; Geyssant, A; Itti, R; Salen, P | 1 |
| Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B | 1 |
| Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Miltiadous, GA; Tsimihodimos, VK; Tzallas, CS | 1 |
| Cadarso, C; de la Serna, G | 1 |
| Bairaktari, E; Elisaf, MS; Kiortisis, DN; Millionis, H | 1 |
| Chan, NN; Chow, FC | 1 |
| Balkau, B; Chesnier, MC; Eschwège, E; Maison, P; Mennen, L; Sapinho, D; Sigalas, J | 1 |
| Cwalina, L; Herman, ZS; Kalina, Z; Kowalski, J; Lebek, M; Okopien, B; Wisniewska-Wanat, M; Zielinski, M | 1 |
| Katona, A; Mark, L; Marki-Zay, J | 1 |
| Achimastos, A; Bairaktari, E; Elisaf, M; Liberopoulos, E; Miltiadous, G; Nikas, S; Tsimihodimos, V | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Ceska, R; Malik, J; Melenovsky, V; Pisarikova, A; Poledne, R; Simek, J; Skrha, J; Stavek, P; Wichterle, D | 1 |
| Gervois, P; Kleemann, R; Koenig, W; Kooistra, T; Percevault, F; Pilon, A; Staels, B | 1 |
| Bairaktari, E; Elisaf, M; Kakafika, A; Kostoula, A; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V | 1 |
| Dobordzhginidze, LM | 1 |
| Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR | 1 |
| Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S | 1 |
| Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
| Cordan, J; Guclu, S; Heper, Y; Saltan, Y; Serdar, A; Serdar, Z; Yesilbursa, D | 1 |
| Herman, ZS; Krysiak, R; Okopień, B | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Cieślak, D; Duchnowicz, P; Koter-Michalak, M; Mackiewicz, K | 1 |
| Bovy, A; Hall, R; Herbers, K; Kleemann, R; Kooistra, T; Rein, D; Schijlen, E; Sonnewald, U; Verschuren, L | 1 |
| Chou, CW; Hsiao, SH; Kao, PC; Lin, CY; Ou, HY; Wu, TJ | 1 |
| Atalar, E; Beyazit, Y; Guven, GS; Haznedaroglu, IC; Kekilli, M; Kilicarslan, A; Oz, G; Ozer, N; Sahiner, L; Sozen, T; Yavuz, B | 1 |
| Rosenson, RS | 1 |
| Krysiak, R; Okopien, B; Pruski, M | 1 |
| Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B | 1 |
| Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Quon, MJ; Sakuma, I; Shin, EK; Shin, KC | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopień, B | 1 |
| Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I | 1 |
1 review(s) available for fenofibrate and fibrinogen
| Article | Year |
|---|---|
[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Triglycerides | 2004 |
20 trial(s) available for fenofibrate and fibrinogen
| Article | Year |
|---|---|
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
Topics: Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyspepsia; Exercise Test; Female; Fenofibrate; Fibrinogen; Heart Rate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Patient Dropouts; Physical Endurance; Simvastatin; Stroke Volume; Treatment Outcome; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1999 |
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 1999 |
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Male; Middle Aged; Treatment Outcome; Triglycerides; Uric Acid | 1999 |
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Drug Combinations; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2000 |
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrinogen; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thrombosis; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides | 2001 |
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
Topics: Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2002 |
Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Arteriosclerosis; Biomarkers; C-Reactive Protein; Female; Fenofibrate; Fibrinogen; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Male; Middle Aged | 2004 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Glycated Hemoglobin; Homocysteine; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Male; Middle Aged; Models, Biological; Smoking; Treatment Outcome | 2005 |
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
Topics: Adult; Biomarkers; Blood Glucose; Cytokines; Diet; Female; Fenofibrate; Fibrinogen; Glucose Intolerance; Glucose Tolerance Test; Hemostasis; Hormones; Humans; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Male; Middle Aged; Monocytes | 2006 |
[The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia].
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; C-Reactive Protein; Dyslipidemias; Erythrocyte Membrane; Female; Fenofibrate; Fibrinogen; Humans; Male; Middle Aged; Obesity; Thiobarbituric Acid Reactive Substances | 2006 |
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Topics: Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Fenofibrate; Fibrinogen; Humans; Hyperlipidemias; Hypolipidemic Agents; Outpatients; Proinsulin; Risk Factors; Triglycerides | 2007 |
Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.
Topics: Adult; Carboxypeptidase B2; Endothelium, Vascular; Female; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pulsatile Flow; Vasodilation | 2008 |
Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
Topics: Adiponectin; Adult; Aged; Biomarkers; C-Reactive Protein; Chemokine CCL2; Chemokine CCL3; Female; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Interleukin-1beta; Male; Metabolic Syndrome; Middle Aged; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2009 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibrinogen; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Placebos; Plasminogen Activator Inhibitor 1; Risk Factors | 2009 |
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Metabolic Syndrome; Plasminogen Activator Inhibitor 1; Prediabetic State; Pyrroles | 2010 |
Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Topics: Adiponectin; Analysis of Variance; Apolipoprotein A-I; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Dietary Supplements; Fatty Acids, Omega-3; Female; Fenofibrate; Fibrinogen; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Male; Middle Aged; Republic of Korea; Single-Blind Method; Time Factors; Treatment Outcome; Triglycerides; Vasodilation | 2012 |
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intolerance; Hemostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Prediabetic State; Single-Blind Method | 2013 |
13 other study(ies) available for fenofibrate and fibrinogen
| Article | Year |
|---|---|
[Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?].
Topics: Blood Viscosity; Coronary Circulation; Coronary Disease; Drug Evaluation; Erythrocyte Aggregation; Exercise Test; Fenofibrate; Fibrinogen; Heart; Humans; Lipids; Microcirculation; Myocardial Infarction; Propionates; Radionuclide Imaging; Thallium Radioisotopes | 1989 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
[The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Topics: Adult; Aged; Female; Fenofibrate; Fibrinogen; Heterozygote; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged | 1996 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides | 1999 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Fenofibrate; Fibrinogen; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2001 |
A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration.
Topics: Adult; Body Mass Index; Cohort Studies; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Sex Factors; Treatment Outcome | 2002 |
Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.
Topics: Antibodies, Bacterial; Apolipoprotein A-I; Apolipoproteins B; Chlamydophila pneumoniae; Cholesterol; Cholesterol, HDL; Coronary Artery Disease; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins; Triglycerides | 2002 |
The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Indapamide; Male; Middle Aged; Triglycerides; Uric Acid | 2002 |
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.
Topics: Acute-Phase Reaction; Animals; Apolipoproteins; Down-Regulation; Fenofibrate; Fibrinogen; Haptoglobins; Humans; Hypolipidemic Agents; Interleukin-6; Mice; Receptors, Cytoplasmic and Nuclear; Serum Amyloid A Protein; Signal Transduction; Transcription Factors | 2004 |
The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Topics: Adult; Aryldialkylphosphatase; C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrinogen; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2005 |
Transgenic flavonoid tomato intake reduces C-reactive protein in human C-reactive protein transgenic mice more than wild-type tomato.
Topics: Alanine Transaminase; Animals; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Diet; E-Selectin; Fenofibrate; Fibrinogen; Flavonoids; Fruit; Humans; Mice; Mice, Transgenic; Plants, Genetically Modified; Risk Factors; Solanum lycopersicum | 2006 |
Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature).
Topics: Amputation, Surgical; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Intermittent Claudication; Ischemia; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Predictive Value of Tests; Risk Factors; Treatment Outcome | 2018 |